PP2A methylesterase, PME‐1, and PP2A methyltransferase, LCMT‐1, control sensitivity to impairments caused by injury‐related oligomeric tau
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Sowmya N Sundaresh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Pathology, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: tau Proteins, Carboxylic Ester Hydrolases, Protein O-Methyltransferase, Brain Injuries, Traumatic. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paul G. Allen Frontiers Group, U.S. Department of Defense.
Abstract (Originalsprache)
INTRODUCTION Oligomeric species of tau are a hallmark of Alzheimer's disease (AD). Given the evidence implicating protein phosphatase 2A (PP2A) in the molecular pathogenesis of tauopathies, we sought to determine whether manipulating the expression of enzymes that regulate PP2A activity, such as leucine carboxyl methyltransferase 1 (LCMT‐1) and protein methylesterase 1 (PME‐1), would alter pathological responses to oligomeric tau. METHODS We tested the effect of LCMT‐1 and PME‐1 overexpression on cognitive and electrophysiological impairments caused by exposure to either recombinant oligomeric human tau or oligomeric tau prepared from mice subjected to blast‐induced traumatic brain injury. RESULTS We found that LCMT‐1 overexpression reduced sensitivity while PME‐1 overexpression increased sensitivity to tau‐induced impairments. Moreover, shockwave exposure increased the propensity of endogenous tau to form toxic oligomers. DISCUSSION These results suggest that manipulating LCMT‐1 or PME‐1 activity may represent novel therapeutic approaches for disorders involving exposure to pathogenic forms of oligomeric tau. Highlights LCMT‐1 and PME‐1 overexpression alters sensitivity to oligomeric tau‐induced impairments. Blast‐induced traumatic brain injury increases the propensity of tau to oligomerize. Pathogenic tau‐induced cognitive impairments were dependent on its oligomeric form.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Cell Pathology, Columbia University, New York, New York, USA.
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
- Department of Biomedical Engineering, Columbia University, New York, New York, USA.
- Department of Biology, Pace University, New York, New York, USA.
- Department of Translational Neuroscience, Michigan State University, Grand Rapids, Michigan, USA.
- Department of Medicine, Columbia University, New York, New York, USA.
Förderung
- Paul G. Allen Frontiers Group
- U.S. Department of Defense
Zitieren
APA
Sundaresh, S. N., Vogel, E. W., Hue, C. D., Zhang, H., Staniszewski, A., Berman, H. L., Gill, Z., Asam, K., Liang, S., Shen, L., Gnanaprakash, M., Acquarone, E., Masone, A., Fà, M., Kanaan, N. M., Morrison, B., Arancio, O., & Nicholls, R. E. (2025). PP2A methylesterase, PME‐1, and PP2A methyltransferase, LCMT‐1, control sensitivity to impairments caused by injury‐related oligomeric tau. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70947
Vancouver
Sundaresh SN, Vogel EW, Hue CD, Zhang H, Staniszewski A, Berman HL, et al. PP2A methylesterase, PME‐1, and PP2A methyltransferase, LCMT‐1, control sensitivity to impairments caused by injury‐related oligomeric tau. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70947
BibTeX
@article{Sundaresh2025,
author = {Sundaresh, Sowmya N and Vogel, Edward W and Hue, Christopher D and Zhang, Hong and Staniszewski, Anna and Berman, Hanna L and Gill, Zafar and Asam, Kesava and Liang, Siqi and Shen, Liwei and Gnanaprakash, Madhumathi and Acquarone, Erica and Masone, Antonio and Fà, Mauro and Kanaan, Nicholas M and Morrison, Barclay and Arancio, Ottavio and Nicholls, Russell E},
title = {PP2A methylesterase, PME‐1, and PP2A methyltransferase, LCMT‐1, control sensitivity to impairments caused by injury‐related oligomeric tau},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70947}
}
EUVIMED